BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin’s Development Program in Anti-cancer Indications

NEXT STORY
PDS Biotechnology Corporation Announces Closing of Approximately $52 Million Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares
PREV STORY
Artios Pharma Publishes Preclinical Data on The First Selective Small Molecule Polθ Polymerase Inhibitor in Nature Communications
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Moleculin Receives Approval for Leukemia Clinical Trial

HOUSTON, June 20, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq:MBRX) ("Moleculin" or the ...

author_avatar
NASDAQ Market News

Novome Biotechnologies and Genentech Enter into a Strategic Collaboration to Develop Targets Against Inflammatory Bowel Disease

author_avatar
NASDAQ Market News

Research on Lodonal for HIV related GI complications featured in Plus Magazine

ORLANDO, Fla., July 19, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, ...

author_avatar
NASDAQ Market News